Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018

This report originally appeared on cdc.gov. To view the full report, click here. Additionally, you can find the original report for download here: [Download not found]

On December 3rd, a new Morbidity and Mortality Weekly Report (MMWR)  was released highlighting vital signs for HIV virus testing, suppression, and pre-exposure prophylaxis.

Following is a brief summary of the article, “Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018.”

Summary

What is already known about this topic?

The approximately 38,000 new human immunodeficiency virus (HIV) infections that occur annually in the United States are preventable through testing, treatment, and preexposure prophylaxis (PrEP). A proposed initiative seeks to reduce new infections by at least 90% by 2030. The targets for the initiative are at least 95% for testing and treatment and 50% for PrEP.

What is added by this report?

In 2017, 85.8% of persons with HIV infection had received a diagnosis, and 62.7% of persons with diagnosed HIV infection had a suppressed viral load. In 2018, PrEP had been prescribed to 18.1% of persons with indications.

What are the implications for public health practice?

Accelerated efforts to diagnose, treat, and prevent HIV infection are urgently needed.

Read the full report. 

NIH’s Dr. Dieffenbach Discusses How Implementation Research Is Supporting EHE Jurisdictions

This video article originally appeared on HIV.gov. To see the full article, click here.

NIH recently invested $11.3 million to find the most effective ways to diagnose, prevent, and treat HIV using highly effective methods that are already available, including pre- and post-exposure prophylaxis (PrEP and PEP) and antiretroviral therapy.

In this video conversation, Carl Dieffenbach, PhD, Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, discusses NIH’s investment in these implementation research projects, which will take place in 43 of the 57 jurisdictions prioritized in Phase I of the Ending the HIV Epidemic: A Plan for America (EHE) initiative.

The funds will help researchers at 23 Centers for AIDS Research and AIDS Research Centers to investigate the best ways to deliver evidence-based interventions and services for those at disproportionate risk for HIV, including Black and Latinx women and men, transgender women, and youth aged 13-24 years. They will also work with local health officials and community groups to design and test implementation techniques that take local issues into account.

Read more about the implementation research awards in this blog post. To learn more about the Ending the HIV Epidemic initiative, visit HIV.gov and sign up for our listserv to stay up to date on the latest EHE developments.

World AIDS Day, 2019

A Message from CHIPTS:

On this World AIDS Day, we stand in solidarity with all those living with, at risk for, or affected by HIV across the world.  It is both a sobering and an exciting time.

We are currently faced with a challenge and an opportunity for bending the arc of new HIV infections toward zero in the United States. The U.S. Government has identified “Ending the HIV Epidemic” as a top issue for ​the administration – promising ​resource support necessary to end the domestic HIV epidemic. ​This is a clarion call for cooperation and synergy​ between public health professionals, clinicians, scientists and communities. ​ Bold initiatives are required. Now is the time.

Implementing wider reaching, better and faster HIV ​treatment and prevention will uncover known and unknown challenges to the goal of eliminating HIV. We know the current ​models of treatment and prevention, organized around getting medications into the hands of those who need them – especially people living with HIV – has helped improve health and reduce new transmissions. Pre-exposure prophylaxis, antiretroviral medications used to support remaining HIV-negative, has potential for further reducing new infections.

Disparities in access to care, medical mistrust, racism, sexism, homophobia, transphobia, and HIV-associated stigma are all contributing to unequal benefits of the cornucopia of tools we currently possess to both treat those affected by, and at-risk for HIV.  We must address these as an overarching priority or we will fail:  we will fail ourselves, our colleagues, our patients, our clients, our constituents, and the epidemic writ large.

The potential for an infusion of new resources into ending the HIV epidemic is therefore both exciting and daunting.  We must fight in an environment in which health systems increasingly seem at cross-purposes or even antithetical to these goals and visions.

We must recognize and address that a sizeable minority, perhaps 15%-20% of people living with HIV or with high risks for HIV infection, need more, better, and/or different interventions – now and into the foreseeable future – to ensure consistent adherence with HIV care and persistence with HIV prevention. This part of the strategy recognizes that for many in this minority, chronic and relapsing conditions often interfere with efforts to sustain consistent medication taking, whether for HIV care or HIV prevention. These conditions include mental health and/or substance use disorders, in addition to the “isms” listed above.

We need partnerships and regional responses. We must recognize the impacts of gentrification and other social and economic factors displace large numbers of Americans from affordable housing, which challenges implementation of new resources in HIV-care and prevention so that they reach the people who need them.

We need better, faster, more flexible ways to measure HIV outcomes and current factors that correlate with outcomes from investments across regions. Health jurisdictions are not configured to measure regional outcomes.

Making measurable progress in ending the HIV epidemic in the U.S. is a thrilling possibility. And to reach this objective carries the real possibility that we will learn that improving health outcomes for the most of us are directly tied to ensuring that we improve the health outcomes for all of us.   But only if all involved work together, with redoubled and common resolve, to end these inequities, address the clearly identified social determinants of health, in partnership and on equal footing with more conventional advances in biomedical science.

Here’s to thinking out of the box on this World AIDS Day.

Through Positive Eyes: Storytelling Exhibit at UCLA’s Fowler Museum

This post was originally published on fowler.ucla.edu. You can view and download the press released document here: Through Positive Eyes Exhibition at the Fowler Museum (2019-20) - Summary

THROUGH POSITIVE EYES 
SEPTEMBER 15, 2019–FEBRUARY 16, 2020

To help end the stigma around HIV/AIDS and empower people from around the world who are living with the virus, a new exhibition at the Fowler Museum at UCLA will highlight the stories
and images of HIV-positive individuals and their perspectives on the epidemic. The exhibition is co-curated by David Gere, UCLA Professor of World Arts and Cultures, who, with photographer Gideon Mendel, co-founded Through Positive Eyes, which is an art project and an exhibition created in collaboration with people living with HIV/AIDS.

Launched in 2007 by UCLA’s Art & Global Health Center, Through Positive Eyes puts cameras in the hands of the people most deeply affected by HIV to create personal photo essays. Entering
its 12th year of intensive photography workshops, regional public exhibitions, and now, a touring global exhibition, the endeavor coalesces around one core tenet: a belief that challenging stigma
against people living with HIV/AIDS is the most effective method for combating the epidemic.

There will be a range of artivist in-gallery performances happening through October 6, 2019–February 16, 2020. Please see a summary of the exhibit’s schedule below and check out the exhibit’s website here for further details. We strongly encourage you to attend and show support.

SCHEDULE
Wednesdays 5–8:00pm
Beginning at 5pm, and on the hour thereafter. Last performance begins at 7:00pm.
Oct. 16, 23, 30
Nov. 6, 13, 20
Dec. 4, 11, 18
Jan. 8, 15, 22, 29
Feb. 5, 12

Sundays 1-4:00pm
Beginning at 1pm, and on the hour thereafter. Last performance begins at 3:00pm.
Oct. 6, 13, 20, 27
Nov. 3, 10, 17, 24
Dec. 1, 8, 15, 22, 29
Jan. 5, 12, 19, 26
Feb. 2, 9, 16

MMWR: Racial/Ethnic and Age Group Differences in Opioid and Synthetic Opioid–Involved Overdose Deaths Among Adults

This report originally appeared on cdc.gov. To view the full report, click here. Additionally, you can find the original report for download here: MMWR: Racial/Ethnic and Age Group Differences in Opioid and Synthetic Opioid–Involved Overdose Deaths Among Adults Aged 18 Years in Metropolitan Areas

On November 1st, the Office of the Assistant Secretary for Health and the Centers for Disease Control and Prevention released a new Morbidity and Mortality Weekly Report (MMWR) article highlighting differences in U.S. opioid death rates by demographic and geographic characteristics.

Following is a brief summary of the article, “Racial/Ethnic and Age Group Differences in Opioid and Synthetic Opioid–Involved Overdose Deaths Among Adults Aged ≥18 Years in Metropolitan Areas — United States, 2015–2017.”

Summary
What is already known about this topic?

Opioid-involved overdose death rates in the United States differ by demographic and geographic characteristics. Illicitly manufactured fentanyl and fentanyl analogs have fueled recent increases in opioid-involved overdose deaths. In 2017, synthetic opioids were involved in nearly 60% of opioid-involved overdose deaths; however, the level of involvement by racial/ethnic age groups in metropolitan areas has not been explored.

What is added by this report?

From 2015 to 2017, nearly all racial/ethnic groups and age groups experienced significant increases in opioid-involved and synthetic opioid–involved overdose death rates, particularly blacks aged 45–54 years (from 19.3 to 41.9 per 100,000) and 55–64 years (from 21.8 to 42.7) in large central metro areas. The increased involvement of synthetic opioids in overdose deaths is changing the demographics of the opioid overdose epidemic.

What are the implications for public health practice?

Culturally competent interventions are needed to target populations at risk; these interventions include increasing awareness about synthetic opioids in the drug supply and expanding evidence-based interventions, such as naloxone distribution and medication-assisted treatment.

Read the full report. 

 

CHIPTS Recognizes and Affirms The 1619 Project

“America was not yet America, but this was the moment it began. No aspect of the country that would be formed here has been untouched by the 250 years of slavery that followed. On the 400th anniversary of this fateful moment, it is finally time to tell our story truthfully.” – The 1619 Project, New York Times

Original Artwork by Adam Pendelton, The 1619 Project, The New York Times. August 18, 2019.

On August 20th, 2019, The New York Times launched The 1619 Project, an acknowledgement of the 400th anniversary of the arrival of Africans in America, hence the beginning of American slavery. By presenting the year 1619 as our nation’s rightful birth year, this major initiative aims to re-frame our history, urging us to recognize the role(s) of slavery and the contributions of black Americans within the narratives we share as a country. Containing a series of essays reflecting the dynamics of everyday American life and a unique collection of original literary works from contemporary black writers, the project dissects the many systems rooted in slavery and its aftermath, including mass incarceration, police brutality, and health inequity.

This anniversary has significance for public health, as racial inequalities persist amidst significant health disparities. At the same time, the urgency for public health systems to address these complexities remains. At a moment in US history when the role of government in healthcare is controversial, envisioning 1619 to 2019 as 400 years of inequality will be a crucial step for health care providers, researchers, and community partners. This reflection within public health forums can bring substantial benefits in establishing anti-racist and health equitable methods responsive to structural racism’s consequential influence.

Essay by Nikole Hannah-Jones, Creator of The 1619 Project, The New York Times. August 18, 2019.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Therefore, CHIPTS acknowledges and affirms The 1619 Project, and works to integrate similar anti-racist paradigms within  our mission to promote collaborative research, foster networking, and support capacity building among communities and agency partners in efforts to eliminate new HIV infections and health disparities among key populations with HIV-associated comorbidities. In our current work, CHIPTS is directly addressing this intention with the upcoming conference, “Addressing Medical Mistrust in Black Communities: Implications for HIV and other Conditions”. This forum aims to improve understanding of the historical foundations of medical mistrust in black communities, dissect its effects on health care behaviors, and discuss necessary system level changes in a manner that encourages healthcare engagement and improves health outcomes. It will occur Tuesday, November 19th from 8AM-1PM. All are welcome to attend.

Lastly, we encourage you to read the original 1619 Project article published by The New York Times Magazine. To learn more about 1619’s dynamic relationship to public health, please also see, “400 Years of Inequality Since Jamestown of 1619” from AJPH History.

The PDF Versions of both articles are available for download below.

[Download not found]

 

[Download not found]
Steve Shoptaw, director of the UCLA Center for HIV Identification, Prevention and Treatment Services

UCLA receives $395,000 from NIH for HIV prevention and treatment

This article originally appeared on newroom.ucla.edu. The PDF is also available for download below. 

UCLA’s Center for HIV Identification, Prevention and Treatment Services has received $395,000 from the National Institutes of Health for AIDS prevention, treatment and response to outbreaks.

Three, one-year grants, awarded by the NIH’s National Institute of Mental Health, will support research to prevent new HIV transmissions, treat people living with HIV, and respond to potential outbreaks of the disease.

“These funds will gather findings to guide future projects that when implemented, will measurably reduce HIV transmission and improve health for those living with HIV/AIDS , especially for those also living with mental health and substance use disorders,” said Steve Shoptaw, director of the Center for HIV Identification, Prevention and Treatment Services. “These grants will not only provide us with the opportunity to collect pilot data, but to engage community and agency partners, leading to more innovative and collaborative science that are needed to end the HIV epidemic.”

The funding stems from President Donald J. Trump’s stated aim to end the HIV epidemic in the U.S. in the next 10 years. The president’s program, “Ending the HIV Epidemic: A Plan for America,” aims to reduce new HIV infections by 75% in five years and by at least 90% in 10 years.

The three funded projects are as follows:

  • A regional response to HIV eradication efforts in Southern California counties, led by Shoptaw, a professor of family medicine and of psychiatry and biobehavioral sciences at the David Geffen School of Medicine at UCLA. Under this project, UCLA will collaborate with health departments and residents living with or at risk for HIV in Los Angeles, Orange, Riverside and San Bernardino counties.
  • Another project, led by Ronald Brooks, an assistant professor of family medicine at the medical school, will assess the feasibility of using apps, tele-health, text messaging and other digital technologies to encourage the use of PrEP, or pre-exposure prophylaxis, among men who have sex with men and transgender women of color.
  • The third project will lay the groundwork for the rollout of long-lasting, injectable anti-retroviral treatment, a therapy under consideration for marketing approval by the U.S. Food and Drug Administration and expected to become commercially available soon. Dr. Raphael Landovitz, professor of medicine in division of infectious diseases, is leading this project.
[Download not found]

Colloquium: “Impact of HIV/AIDS in the Latinx Community”

October 10th, 2019- This month’s commission meeting featured a panel focused on the impacts of HIV/AIDS in the Latinx Community. Our panelists included  Jose Vasquez from APLA’s HIVE Program, Johanna Padilla from the Los Angeles LGBT and Trans Wellness Center,  Thelma Garcia from East Los Angeles Women’s Center, and Commissioner Carlos Moreno. The panel was moderated by Jorge Diaz.

The discussion provided insight into the experiences of Latinx/Latino Indigenous narratives, with major objectives to highlight the urgency of the HIV/AIDS epidemic within these community spaces and present deeper understandings to the issues faced. Challenges were expressed regarding the unique barriers of language, cultural/spiritual stigmas, knowledge of prevention and treatment services, and fear. Greater solutions were also noted, including a call for more trauma-informed services, compassion from providers, education of youth and cis/het populations, and more visible identity-specific support systems. Overall, the conversation was intersectional, inclusive, and non-monolithic.

You can find the flyer available for download below as well as the full video of the panel (also available on Youtube).

Impact of HIV/AIDS in Latinx Communities - Flyer

 

CHIPTS hosts a monthly HIV Research and Community Colloquia Series in collaboration with the Los Angeles County Commission on HIV to highlight current issues and conversations surrounding HIV. Click here for past lectures and check out the events page for more information on future Colloquia presentations!

CHIPTS Kick Start Program

2019-2020 CHIPTS Community-Research Kick Start Grant

CHIPTS is pleased to announce a new funding opportunity to help support workshops, planning meetings, symposia, or other activities that are designed to promote new science, foster new collaborations, or increase capacity building. The purpose of the program is to “kick start” the development of new research ideas and other projects to address emerging issues and needs of communities most impacted by HIV. Community collaboration and engagement are strongly encouraged.   The proposed activities must contribute towards CHIPTS scientific theme of addressing the intersection of HIV/AIDS treatment and prevention and mental health and/or substance use co-morbidities. The funding amount can range from $500 up to $5,000 direct costs, based on proposed activities. Read More

 

CDC’s Division of HIV/AIDS Prevention Data to Care Workgroup

This article originally appeared on HIV.gov. To see the full article, click here

A collection of articles recently published in the Journal of Acquired Immune Deficiency Syndromes (JAIDS) takes a deep-dive into a relatively new HIV prevention tool referred to as Data to Care, or simply D2C. D2C is a public health strategy that uses surveillance and other data to improve continuity of HIV care for persons with HIV by identifying those who are in need of medical care or other services and facilitating linkage to these services. Full article